Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2

BACKGROUND: Cancer immunotherapy with monoclonal antibodies and chimeric antigen receptor (CAR) T cell therapies can benefit from selection of new targets with high levels of tumor specificity and from early assessments of efficacy and safety to derisk potential therapies. METHODS: Employing mass sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellizzari, Giulia, Martinez, Olivier, Crescioli, Silvia, Page, Robert, Di Meo, Ashley, Mele, Silvia, Chiaruttini, Giulia, Hoinka, Jan, Batruch, Ihor, Prassas, Ioannis, Grandits, Melanie, López-Abente, Jacobo, Bugallo-Blanco, Eva, Ward, Malcolm, Bax, Heather J, French, Elise, Cheung, Anthony, Lombardi, Sara, Figini, Mariangela, Lacy, Katie E, Diamandis, Eleftherios P, Josephs, Debra H, Spicer, James, Papa, Sophie, Karagiannis, Sophia N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194339/
https://www.ncbi.nlm.nih.gov/pubmed/34112739
http://dx.doi.org/10.1136/jitc-2020-002140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194339/
https://www.ncbi.nlm.nih.gov/pubmed/34112739
http://dx.doi.org/10.1136/jitc-2020-002140

Ejemplares similares